Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.
Molecular therapy. Nucleic acids
View this publicationMolecular therapy. Nucleic acids
View this publicationImmunity
View this publicationThe lancet. Gastroenterology & hepatology
View this publicationFrontiers in microbiology
View this publicationNeurological research and practice
View this publicationVASA. Zeitschrift fur Gefasskrankheiten
View this publicationThe American journal of tropical medicine and hygiene
View this publicationMolecular neurobiology
View this publicationHemaSphere
View this publicationJournal of clinical medicine
View this publication